AR and prostate carcinoma: In animal studies, HRR genes are shown to interact with androgen receptor signaling, which regulates DNA repair in prostate cancer [22, 23], suggesting that a combination of PARP inhibitors and ARAT may be more effective in patients with HRR mutations.